Forum Financial Management LP Reduces Stock Position in Biogen Inc. $BIIB

Forum Financial Management LP cut its position in Biogen Inc. (NASDAQ:BIIB) by 67.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,890 shares of the biotechnology company’s stock after selling 3,997 shares during the period. Forum Financial Management LP’s holdings in Biogen were worth $346,000 at the end of the most recent quarter.

Several other institutional investors have also recently modified their holdings of the company. Rothschild Investment LLC increased its holdings in Biogen by 12.3% in the 4th quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock worth $90,000 after buying an additional 56 shares during the period. Itau Unibanco Holding S.A. lifted its stake in Biogen by 24.4% during the 4th quarter. Itau Unibanco Holding S.A. now owns 337 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 66 shares during the period. Advisory Services Network LLC lifted its stake in Biogen by 3.9% during the 3rd quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock valued at $251,000 after acquiring an additional 68 shares during the period. Davis Investment Partners LLC boosted its holdings in shares of Biogen by 1.7% in the 4th quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock valued at $778,000 after acquiring an additional 71 shares during the last quarter. Finally, Optas LLC boosted its holdings in shares of Biogen by 4.5% in the 4th quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock valued at $300,000 after acquiring an additional 73 shares during the last quarter. 87.93% of the stock is currently owned by hedge funds and other institutional investors.

Biogen Stock Performance

NASDAQ BIIB opened at $216.06 on Wednesday. The stock has a fifty day simple moving average of $194.96 and a 200-day simple moving average of $186.27. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. The stock has a market cap of $31.90 billion, a PE ratio of 23.18 and a beta of 0.20. Biogen Inc. has a twelve month low of $121.05 and a twelve month high of $219.72.

Biogen (NASDAQ:BIIB) last announced its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.95 by $0.62. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company had revenue of $2.48 billion for the quarter, compared to analyst estimates of $2.29 billion. During the same quarter in the previous year, the company earned $3.02 earnings per share. The firm’s quarterly revenue was up 1.9% compared to the same quarter last year. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. Equities analysts anticipate that Biogen Inc. will post 13.95 earnings per share for the current year.

Analyst Upgrades and Downgrades

BIIB has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating on shares of Biogen in a report on Thursday, May 14th. Needham & Company LLC upped their price objective on Biogen from $255.00 to $256.00 and gave the stock a “buy” rating in a research report on Monday. Canaccord Genuity Group lifted their price objective on shares of Biogen from $230.00 to $245.00 and gave the company a “buy” rating in a report on Wednesday, April 1st. UBS Group upgraded Biogen from a “neutral” rating to a “buy” rating and increased their price target for the stock from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Finally, Argus raised Biogen to a “hold” rating in a research note on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $217.41.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Needham raised its price target on Biogen to $256 and reiterated a Buy rating, citing stronger-than-expected Spinraza HD momentum and progress across the company’s pipeline. Biogen: Key Takeaways From Needham’s Meeting With Top Management
• Positive Sentiment: Biogen said it will showcase new Alzheimer’s disease data at AAIC 2026, including Phase 2 CELIA results for diranersen and additional lecanemab analyses, which could reinforce confidence in one of its key growth areas. Biogen to Highlight Breadth of Alzheimer’s Disease Portfolio at AAIC 2026
• Positive Sentiment: Biogen was highlighted alongside other biotech leaders hitting new 52-week highs, reflecting broader sector strength and momentum in the stock. Biotech Bigwigs ABBV, JNJ, BIIB & LLY Hit New 52-Week Highs
• Neutral Sentiment: Zacks added Biogen-related ticker BBIB to its Strong Sell list, but this appears to be a separate ticker and not a direct negative on Biogen Inc. itself. New Strong Sell Stocks for June 30th
• Negative Sentiment: One report said Biogen is trimming Apellis-related R&D spending and pausing or ending investment in most legacy programs after its acquisition, which may raise integration and capital-allocation concerns. Biogen trims Apellis pipeline and R&D team after $5.6bn takeover
• Negative Sentiment: Biogen was also mentioned in a class action settlement notice, which could keep some legal overhang on the shares, though the announcement itself is not a new operational setback. Block & Leviton LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Common Stock of Biogen, Inc. – BIIB

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.